Latest Security News

HyTerra Limited has appointed Riley Kemp as its new CEO, aiming to accelerate growth and strengthen its position in the emerging geologic hydrogen sector.

Echelon Resources has signed a term sheet with the Northern Territory’s Power and Water Corporation to supply gas through 2034, including plans for four new wells that could significantly increase output from the Amadeus Basin.

Medallion Metals has raised $60 million through a placement and share purchase plan to advance its integrated gold-copper development strategy, targeting first production in early 2027.

The ASX has suspended trading of Olympio Metals and Thorney Technologies shares due to delayed periodic report filings, highlighting ongoing compliance challenges for both companies.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Diatreme Resources has submitted the Draft Environmental Impact Statement for its Northern Silica Project, marking a significant step toward regulatory approval and highlighting its potential to boost regional economies and support global solar energy growth.

Resolution Minerals appoints Dr Adam Roper as Chief Metallurgist to advance antimony, tungsten, and gold processing at its Idaho Horse Heaven Project, aligning with US defense supply chain goals.

IperionX partners with Carver Pump to fast-track production of critical titanium components for U.S. Navy ships, aiming to cut lead times from over a year to under a week.

Biotron Limited’s BITO securities have been suspended from ASX trading due to non-compliance with key listing rules, raising questions about the company’s next steps.

Mt Malcolm Mines has executed a binding agreement to acquire key components of a 500,000 tonnes per annum gold processing plant, positioning itself for future self-processing and toll-milling opportunities in the prolific Leonora gold region.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.